Effects of daily versus weekly teriparatide for medication‐related osteonecrosis of the jaw: A case–control study
Oral Diseases · 2024-07 · 30 (5) · 3286-3295
DOI: 10.1111/odi.14801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 05.11.2023. Verfasst von Kang-Min Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, College of Medicine, Ewha Womans University, Seoul, South Korea. Hauptthemen laut MEDLINE: Teriparatide, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea.
Abstract (Originalsprache)
Introduction
Medication‐related osteonecrosis of the jaw (MRONJ) is uncommon but can result in severe destruction of the jaw. This case–control study investigated the therapeutic effects of daily or weekly administration of teriparatide in the management of MRONJ using a cohort for osteonecrosis of the jaw.
Methods
Patients who were diagnosed with MRONJ and consented to teriparatide administration were assigned either to a group of daily injection or of weekly injection and completed a 4‐week course of injection preoperatively and at least an 8‐week course postoperatively. The control group received either the intraoperative rhBMP treatment (CG_BMP) or no additional perioperative treatment (CG_noBMP). The state of MRONJ was evaluated 2 months (T1) and 6 months (T2) postoperatively for all participants.
Results
Either group of daily injection (8.35 weeks ± 1.58; n = 17) or weekly injection (9.17 ± 3.79; n = 12) showed significantly faster healing than those of CG_BMP (14.40 ± 6.08; n = 25) or CG_noBMP (15.79 ± 9.79; n = 39). MRONJ was resolved completely in 24 out of 29 participants who completed the course of teriparatide injections, whereas 46.9% of CG showed delayed resolution. Multiple regression analysis indicated 7.50 times (95% CI, 1.77–31.82) more likelihood of complete resolution of MRONJ for participants with teriparatide injections.
Conclusion
A course of daily or weekly administration of teriparatide injections may improve treatment outcomes for patients with MRONJ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, College of Medicine, Ewha Womans University, Seoul, South Korea.
- Project for Korean National Cohort for Osteonecrosis of the Jaw.
- Graduate School of Clinical Dentistry, Ewha Womans University, Seoul, South Korea.
- Graduate School of Medicine, Ewha Womans University, Seoul, South Korea.
- Department of Conservative Dentistry, Yonsei University College of Dentistry, Seoul, South Korea.
- Department of Surgery, Division of Plastic and Reconstructive Surgery, Maxillofacial and Airway Orthodontics, School of Medicine, Stanford University, Palo Alto, California, USA.
ORCID-Profile: Jung-Hyun Park, Jin-Woo Kim
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
Zitieren
APA
Kim, K. M., Kim, S., Hwang, H., Kim, H. Y., Kim, D., Park, J. H., Choo, H., & Kim, J. W. (2024). Effects of daily versus weekly teriparatide for medication‐related osteonecrosis of the jaw: A case–control study. Oral Diseases, 30(5), 3286-3295. https://doi.org/10.1111/odi.14801
Vancouver
Kim KM, Kim S, Hwang H, Kim HY, Kim D, Park JH, et al. Effects of daily versus weekly teriparatide for medication‐related osteonecrosis of the jaw: A case–control study. Oral Diseases. 2024;30(5):3286-3295. doi:10.1111/odi.14801
BibTeX
@article{Kim2024,
author = {Kim, Kang-Min and Kim, Sehyang and Hwang, Hyun and Kim, Hey-Yun and Kim, Dohyun and Park, Jung-Hyun and Choo, HyeRan and Kim, Jin-Woo},
title = {Effects of daily versus weekly teriparatide for medication‐related osteonecrosis of the jaw: A case–control study},
journal = {Oral Diseases},
year = {2024},
volume = {30},
number = {5},
pages = {3286--3295},
doi = {10.1111/odi.14801}
}
EUVIMED